J.-Y. Douillard

5.6k total citations · 1 hit paper
59 papers, 1.8k citations indexed

About

J.-Y. Douillard is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, J.-Y. Douillard has authored 59 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 42 papers in Oncology, 31 papers in Pulmonary and Respiratory Medicine and 10 papers in Cancer Research. Recurrent topics in J.-Y. Douillard's work include Colorectal Cancer Treatments and Studies (24 papers), Lung Cancer Treatments and Mutations (22 papers) and Cancer Treatment and Pharmacology (16 papers). J.-Y. Douillard is often cited by papers focused on Colorectal Cancer Treatments and Studies (24 papers), Lung Cancer Treatments and Mutations (22 papers) and Cancer Treatment and Pharmacology (16 papers). J.-Y. Douillard collaborates with scholars based in France, United States and Italy. J.-Y. Douillard's co-authors include Fabrice André, Debyani Chakravarty, Núria López-Bigas, Giampaolo Tortora, Jorge S. Reis‐Filho, Marc Ladanyi, Rodrigo Dienstmann, Nikolaus Schultz, Philippe L. Bédard and Lajos Pusztai and has published in prestigious journals such as Journal of Clinical Oncology, Journal of Hepatology and British Journal of Cancer.

In The Last Decade

J.-Y. Douillard

56 papers receiving 1.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)

2018 391 citations Joaquı́n Mateo, Debyani Chakravarty et al. Annals of Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
J.-Y. Douillard France	15	1.0k	891	475	264	252	59	1.8k
Henry G. Kaplan United States	22	831 0.8×	325 0.4×	396 0.8×	233 0.9×	337 1.3×	79	1.6k
Paul Wheatley‐Price Canada	28	1.1k 1.1×	978 1.1×	309 0.7×	385 1.5×	97 0.4×	133	2.0k
Agnès J. van de Wouw Netherlands	21	1.3k 1.3×	511 0.6×	554 1.2×	142 0.5×	273 1.1×	56	1.7k
Lily Lai United States	25	924 0.9×	371 0.4×	453 1.0×	361 1.4×	271 1.1×	75	1.9k
Gun Min Kim South Korea	18	785 0.8×	549 0.6×	351 0.7×	260 1.0×	136 0.5×	91	1.3k
Maureen Ross United States	20	1.0k 1.0×	288 0.3×	426 0.9×	176 0.7×	233 0.9×	61	1.8k
Pamela Crilley United States	20	622 0.6×	373 0.4×	241 0.5×	165 0.6×	139 0.6×	69	1.8k
David Watkins United Kingdom	22	747 0.7×	446 0.5×	254 0.5×	322 1.2×	201 0.8×	81	1.4k
Daniel Vorobiof South Africa	18	938 0.9×	390 0.4×	300 0.6×	153 0.6×	340 1.3×	61	1.6k
Anne Floquet France	30	1.3k 1.3×	758 0.9×	521 1.1×	442 1.7×	572 2.3×	170	3.3k

Countries citing papers authored by J.-Y. Douillard

Since Specialization

Citations

This map shows the geographic impact of J.-Y. Douillard's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J.-Y. Douillard with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J.-Y. Douillard more than expected).

Fields of papers citing papers by J.-Y. Douillard

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J.-Y. Douillard. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J.-Y. Douillard. The network helps show where J.-Y. Douillard may publish in the future.

Co-authorship network of co-authors of J.-Y. Douillard

This figure shows the co-authorship network connecting the top 25 collaborators of J.-Y. Douillard. A scholar is included among the top collaborators of J.-Y. Douillard based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J.-Y. Douillard. J.-Y. Douillard is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Karapetis, Christos S., Michael J. Sorich, Levi Pederson, et al.. (2024). Fluoropyrimidine type, patient age, tumour sidedness and mutation status as determinants of benefit in patients with metastatic colorectal cancer treated with EGFR monoclonal antibodies: individual patient data pooled analysis of randomised trials from the ARCAD database. British Journal of Cancer. 130(8). 1269–1278. 2 indexed citations

Belli, Carmen, Marc Ladanyi, Nicola Normanno, et al.. (2021). ESMO recommendations on the standard methods to detect RET fusions and mutations in daily practice and clinical research. Annals of Oncology. 32(3). 337–350. 84 indexed citations

Marchiò, Caterina, Maurizio Scaltriti, Marc Ladanyi, et al.. (2019). ESMO recommendations on the standard methods to detect NTRK fusions in daily practice and clinical research. Annals of Oncology. 30(9). 1417–1427. 252 indexed citations

Mateo, Joaquı́n, Debyani Chakravarty, Rodrigo Dienstmann, et al.. (2018). A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT). Annals of Oncology. 29(9). 1895–1902. 391 indexed citations breakdown →

Sobrero, Alberto, Axel Grothey, Timothy Iveson, et al.. (2018). The hard road to data interpretation: 3 or 6 months of adjuvant chemotherapy for patients with stage III colon cancer?. Annals of Oncology. 29(5). 1099–1107. 27 indexed citations

Wu, Yi‐Long, Shun Lü, Hao Sun, et al.. (2018). Pan-Asian adapted Clinical Practice Guidelines for the management of patients with metastatic non-small-cell lung cancer: a CSCO–ESMO initiative endorsed by JSMO, KSMO, MOS, SSO and TOS. Annals of Oncology. 30(2). 171–210. 209 indexed citations

Jordan, Katja-Daniela, Matti Aapro, S. Kaasa, et al.. (2017). European Society for Medical Oncology (ESMO) position paper on supportive and palliative care. Annals of Oncology. 29(1). 36–43. 222 indexed citations

Herrero, F. Rivera, Dominik Paul Modest, Filippo de Braud, et al.. (2017). Outcomes in patients receiving maintenance therapy in two panitumumab (Pmab) first-line trials for metastatic colorectal cancer (mCRC). Annals of Oncology. 28. v176–v176. 1 indexed citations

Gridelli, Cesare, Tudor–Eliade Ciuleanu, M. Dómine Gómez, et al.. (2017). Randomized double blind phase IIb trial in advanced NSCLC patients who did not progress after first line platinum based chemotherapy: Vx-001, a therapeutic cancer vaccine, vs placebo as maintenance therapy. Annals of Oncology. 28. v638–v638. 3 indexed citations

10.

Saloustros, Emmanouil, Kyriaki Michailidou, Giannis Mountzios, et al.. (2017). Report on ESMO/SIOPE European Landscape project key results: Mapping the status and needs in AYA cancer care. Annals of Oncology. 28. v643–v643. 2 indexed citations

11.

Bleiberg, Harry, Genevieve Decoster, Aimery de Gramont, et al.. (2017). A need to simplify informed consent documents in cancer clinical trials. A position paper of the ARCAD Group. Annals of Oncology. 28(5). 922–930. 10 indexed citations

12.

Taı̈eb, Julien, Marc Peeters, Salvatore Siena, et al.. (2016). Importance of tumour symptoms and extent of disease on efficacy of first-line FOLFOX4 ± panitumumab (pmab) in patients (pts) with RAS wild-type (WT)/BRAF WT metastatic colorectal cancer (mCRC) in the PRIME study. Annals of Oncology. 27. vi159–vi159. 1 indexed citations

13.

Bennouna, Jaafar, Emmanuel Chamorey, Marie-Christine Étienne-Grimaldi, et al.. (2012). Phase I Trial of Gemcitabine Combined with Capecitabine and Erlotinib in Advanced Pancreatic Cancer: A Clinical and Pharmacological Study. Chemotherapy. 58(5). 371–380. 2 indexed citations

14.

Burkes, Ronald L., Salvatore Siena, Josep Tabernero, et al.. (2011). 6095 POSTER Randomized, Open-label, Phase 3 Study of Panitumumab (Pmab) With FOLFOX4 Vs FOLFOX4 Alone as 1st-line Treatment for Metastatic Colorectal Cancer (mCRC) – the Role of Hypomagnesemia (Hypomag) on Efficacy. European Journal of Cancer. 47. S420–S420. 3 indexed citations

15.

Renée, N., et al.. (2007). Chronopharmacokinetics of Oral Tegafur and Uracil in Colorectal Cancer Patients. Clinical Pharmacology & Therapeutics. 83(3). 413–415. 17 indexed citations

16.

Delord, J.P., Jaafar Bennouna, Pascal Artru, et al.. (2007). Phase II study of UFT with leucovorin and irinotecan (TEGAFIRI): first-line therapy for metastatic colorectal cancer. British Journal of Cancer. 97(3). 297–301. 13 indexed citations

17.

Quoix, Élisabeth, et al.. (2004). Les thérapeutiques ciblées en oncologie thoracique. Revue des Maladies Respiratoires. 21(3). 527–537.

18.

Douillard, J.-Y. & Joan H. Schiller. (2002). ZD0473 combined with other chemotherapeutic agents for the treatment of solid malignancies. European Journal of Cancer. 38. S25–S31. 6 indexed citations

19.

Klášterský, Jean, M.H. Cullen, David Ball, et al.. (1997). Concurrent treatments and induction treatments for unresectable tumors. Lung Cancer. 17. S27–S28. 2 indexed citations

20.

Bardiès, Manuel, Stéphane Bardet, Alain Faivre-Chauvet, et al.. (1996). Bispecific antibody and iodine-131-labeled bivalent hapten dosimetry in patients with medullary thyroid or small-cell lung cancer.. PubMed. 37(11). 1853–9. 42 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact